↓ Skip to main content

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

Overview of attention for article published in Breast Cancer Research, October 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
3 news outlets
twitter
2 tweeters

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial
Published in
Breast Cancer Research, October 2020
DOI 10.1186/s13058-020-01348-w
Authors

Amelie de Gregorio, Lothar Häberle, Peter A. Fasching, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Thomas W. P. Friedl, Emanuel Bauer, Nikolaus de Gregorio, Miriam Deniz, Visnja Fink, Inga Bekes, Ulrich Andergassen, Andreas Schneeweiss, Hans Tesch, Sven Mahner, Sara Y. Brucker, Jens-Uwe Blohmer, Tanja N. Fehm, Georg Heinrich, Krisztian Lato, Matthias W. Beckmann, Brigitte Rack, Wolfgang Janni

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 16%
Researcher 3 16%
Student > Master 2 11%
Professor 1 5%
Student > Postgraduate 1 5%
Other 0 0%
Unknown 9 47%
Readers by discipline Count As %
Medicine and Dentistry 3 16%
Economics, Econometrics and Finance 1 5%
Nursing and Health Professions 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Neuroscience 1 5%
Other 0 0%
Unknown 12 63%

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 July 2021.
All research outputs
#1,070,194
of 19,012,843 outputs
Outputs from Breast Cancer Research
#95
of 1,770 outputs
Outputs of similar age
#38,357
of 388,587 outputs
Outputs of similar age from Breast Cancer Research
#10
of 100 outputs
Altmetric has tracked 19,012,843 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,770 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,587 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.